Ready to rumble, Ironwood? Activist investor Alex Denner suits up for board-seat bid

Boardroom (Image: Jo Johnston / Pixabay)
Sarissa Capital Management intends to nominate Alex Denner for Ironwood's board. (Jo Johnston/Pixabay)

Activist investor Alex Denner is back at it in biopharma. Just a few months after playing a pivotal role in Sanofi’s Bioverativ acquisition, he has set his sights on Ironwood Pharmaceuticals.

The Massachusetts drugmaker on Monday said it had received word from Denner’s Sarissa Capital Management, which held 1.92 million Ironwood shares at the end of 2017, that it intended to nominate Denner for Ironwood’s board.

It’s not the first communication Ironwood has received from Denner and company either. Members of the pharma’s management team had one introductory meeting with Sarissa representatives before the fund sent over its board notification, the company said.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

The way Wells Fargo analyst David Maris sees it, the development is a positive one given Denner’s “track record for value creation with other firms.”

The company’s inventory of early stage pipeline programs—combined as they are with GI drug Linzess, which Ironwood shares with Allergan—may be mixing investors up, he figures, “as a development stage company may appeal to different investors than a commercial company would.” So, while Maris considers Ironwood’s leaders to be “earnest and capable” and likes their direction, he’s open to the idea that a new board member could potentially “help the company see new ways to unlock value.”

RELATED: The 25 most influential people in biopharma today - Alex Denner

Ironwood, for its part, doesn’t see anything wrong with its current board composition. It has added six new directors since 2013, and the entire nine-director slate has “significant experience that is critical to our business,” the company said.

Still, it stressed that it “maintains open and ongoing communications with its shareholders and welcomes views and opinions that may advance its goal of creating shareholder value.“

RELATED: How did Sanofi win over Bioverativ? It upped its bid—and called on activist investor Alex Denner

If Sarissa’s communication turns out to mark the beginning of a protracted proxy battle, Ironwood could be in trouble. Currently, the company’s pre-IPO shareholders hold super-voting rights in the event of a change-in-control vote, but those rights will disappear at the end of the year—an event that “may leave Ironwood more vulnerable to activist investors,” Maris noted.

Denner, formerly the right-hand man of notorious rebel investor Carl Icahn, has targeted several biopharma companies over the last few years, including Ariad and Aegerion. Most recently, he helped orchestrate Sanofi’s $11.6 billion Bioverativ buy, which redeemed the French drugmaker after failed plays for Medivation and Actelion.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.